Huron Therapeutics

Huron Therapeutics is a biotechnology company focused on the discovery and development of a new class of medicines through targeted protein degradation (TPD). Spun out from the Wyss Institute at Harvard University, the company utilizes a proprietary DNA nanoswitch platform to identify molecular glues and other degraders that can eliminate disease-causing proteins. This innovative screening technology allows for the precise measurement of molecular interactions at the single-molecule level, enabling the discovery of compounds that target proteins previously considered undruggable. Huron Therapeutics is currently in the pre-clinical stage, advancing a pipeline of small molecule therapies primarily for oncology and immunology applications. The company is backed by prominent life science investors, including OrbiMed.